|Trade names||Astenile, Cetovister, 17-Chetovis, Dastonil S, Deandros, Diandrone, Fidelin™, Hormobago, 17-Hormoforin, Intrarosa, 17-Ketovis, Mentalormon, Psicosterone|
|Synonyms||EL-10; GL-701; KYH-3102; Androst-5-en-3β-ol-17-one; 3β-Hydroxyandrost-5-en-17-one; 5,6-Didehydroepiandrosterone; Dehydroisoepiandrosterone|
|By mouth, vaginal (insert), intramuscular injection (as prasterone enanthate), injection (as prasterone sodium sulfate)|
• DHEA sulfate
|Biological half-life||DHEA: 25 minutes
DHEA-S: 11 hours
|Chemical and physical data|
|Molar mass||288.424 g/mol|
|3D model (JSmol)|
|Melting point||148.5 °C (299.3 °F)|
Prasterone, also known as dehydroepiandrosterone (DHEA), is a naturally occurring steroid which is used as a supplement and medication. It is an androstane derivative and a precursor of steroid hormones like testosterone and estradiol. Prasterone has weak androgenic activity, weak estrogenic activity, and neurosteroid activity, and acts as a prohormone of androgens and estrogens depending on its dosage and route of administration. As a medication, prasterone may be used to restore or increase DHEA levels in deficiency or old age, for menopausal women as a weak androgen or to treat vaginal atrophy, and, in its sulfate form, for cervical dilation during childbirth.
- 1 Medical uses
- 2 Side effects
- 3 Chemistry
- 4 Society and culture
- 5 Research
- 6 References
- 7 External links
DHEA and DHEA sulfate are produced by the adrenal glands. In people with adrenal insufficiency such as in Addison's disease, there may be deficiency of DHEA and DHEA sulfate. In addition, levels of these steroids decrease throughout life and are 70 to 80% lower in the elderly relative to levels in young adults. As such, DHEA and DHEA sulfate levels are also lower in older people. Prasterone can be used to increase DHEA and DHEA sulfate levels in adrenal insufficiency and older age. Although there is deficiency of these steroids in such individuals, clinical benefits of supplementation, if any, are uncertain, and there is insufficient evidence at present to support the use of prasterone for such purposes.
In clinical studies of prasterone supplementation, dosages have ranged from 20 to 1,600 mg per day. In people with adrenal insufficiency, oral dosages of 20 to 50 mg/day prasterone have been found to restore DHEA and DHEA-S levels to normal ranges seen in healthy young adults. Conversely, oral dosages of 100 to 200 mg/day prasterone have been found to result in supraphysiological levels of DHEA and DHEA-S.
Prasterone is sometimes used as an androgen in hormone replacement therapy (HRT) for menopause. In addition to prasterone itself, a long-lasting ester prodrug of prasterone, prasterone enanthate, is used in combination with estradiol valerate for the treatment of menopausal symptoms under the brand name Gynodian Depot.
At a high dosage of 1,600 mg/day orally for 4 weeks, treatment of postmenopausal women with prasterone has been found to increase serum levels of DHEA by 15-fold, testosterone by 9-fold, DHEA-S, androstenedione (A4), and dihydrotestosterone (DHT) all by 20-fold, and estrone and estradiol both by 2-fold.
Prasterone, under the brand name Intrarosa, is approved in the United States in a vaginal insert formulation for the treatment of atrophic vaginitis (vaginal atrophy). The mechanism of action of prasterone for this indication is unknown, though it may involve local metabolism of prasterone into androgens and estrogens.
As prasterone sodium sulfate (brand names Astenile, Mylis, Teloin), the sodium salt of prasterone sulfate and an ester prodrug of prasterone, prasterone is used in Japan as an injection for the treatment of insufficient cervical ripening and cervical dilation during childbirth.
Prasterone is produced naturally in the human body, but the long-term effects of its use are largely unknown. In the short term, several studies have noted few adverse effects. In a study by Chang et al., prasterone was administered at a dose of 200 mg/day for 24 weeks with slight androgenic effects noted. Another study utilized a dose up to 400 mg/day for 8 weeks with few adverse events reported. A longer term study followed patients dosed with 50 mg of prasterone for 12 months with the number and severity of side effects reported to be small. Another study delivered a dose of 50 mg of prasterone for 10 months with no serious adverse events reported.
It is not known whether prasterone is safe for long-term use. Some researchers believe prasterone supplements might actually raise the risk of breast cancer, prostate cancer, heart disease, diabetes, and stroke. prasterone may stimulate tumor growth in types of cancer that are sensitive to hormones, such as some types of breast, uterine, and prostate cancer. Prasterone may increase prostate swelling in men with benign prostatic hyperplasia (BPH), an enlarged prostate gland.
Prasterone is a steroid hormone. High doses may cause aggressiveness, irritability, trouble sleeping, and the growth of body or facial hair on women. It also may stop menstruation and lower the levels of HDL ("good" cholesterol), which could raise the risk of heart disease. Other reported side effects include acne, heart rhythm problems, liver problems, hair loss (from the scalp), and oily skin. It may also alter the body's regulation of blood sugar.
Prasterone may promote tamoxifen resistance. Patients on hormone replacement therapy may have more estrogen-related side effects when taking prasterone. This supplement may also interfere with other medicines, and potential interactions between it and drugs and herbs are possible.
Prasterone is possibly unsafe for individuals experiencing pregnancy, breastfeeding, hormone sensitive conditions, liver problems, diabetes, depression or mood disorders, polycystic ovarian syndrome (PCOS), or cholesterol problems.
Prasterone, also known as androst-5-en-3β-ol-17-one, is a naturally occurring androstane steroid and a 17-ketosteroid. It is closely related structurally to androstenediol (androst-5-ene-3β,17β-diol), androstenedione (androst-4-ene-3,17-dione), and testosterone (androst-4-en-17β-ol-3-one). Prasterone is the 5-dehydro analogue of epiandrosterone (5α-androstan-3β-ol-17-one) and is also known as 5-dehydroepiandrosterone or as δ5-epiandrosterone.
Society and culture
Prasterone is the generic name of DHEA in English and Italian and its INN, USAN, and DCIT, while its generic name is prasteronum in Latin, prastérone in French and its DCF, and prasteron in German.
In the United States, prasterone or prasterone sulfate have been advertised, under the names DHEA and DHEA-S, with claims that they may be beneficial for a wide variety of ailments. Prasterone and prasterone sulfate are readily available in the United States, where they are sold as over-the-counter dietary supplements.
Prasterone is legal to sell in the United States as a dietary supplement. It is currently grandfathered in as an "Old Dietary Ingredient" being on sale prior to 1994. Prasterone is specifically exempted from the Anabolic Steroid Control Act of 1990 and 2004. It is banned from use in athletic competition.
In Canada, prasterone is a Controlled Drug listed under Section 23 of Schedule IV of the Controlled Drugs and Substances Act and as such is available by prescription only.
In Australia, a prescription is required to buy prasterone, where it is also comparatively expensive compared to off-the-shelf purchases in US supplement shops. Australian customs classify prasterone as an "anabolic steroid[s] or precursor[s]" and, as such, it is only possible to carry prasterone into the country through customs if one possesses an import permit which may be obtained if one has a valid prescription for the hormone.
Sports and athletics
Prasterone is a prohibited substance under the World Anti-Doping Code of the World Anti-Doping Agency, which manages drug testing for Olympics and other sports. In January 2011, NBA player O. J. Mayo was given a 10-game suspension after testing positive for prasterone. Mayo termed his use of prasterone as "an honest mistake," saying the prasterone was in an over-the-counter supplement and that he was unaware the supplement was banned by the NBA. Mayo is the seventh player to test positive for performance-enhancing drugs since the league began testing in 1999. Rashard Lewis, then with the Orlando Magic, tested positive for prasterone and was suspended 10 games before the start of the 2009-10 season. 2008 Olympic 400 meter champion Lashawn Merritt has also tested positive for prasterone and was banned from the sport for 21 months. Yulia Efimova, who holds the world record pace for both the 50-meter and 200-meter breaststroke, and won the bronze medal in the 200-meter breaststroke in the 2012 London Olympic Games, tested positive for prasterone in an out-of-competition doping test. In 2016 MMA fighter Fabio Maldonado revealed he was taking prasterone during his time with the UFC.
A meta-analysis of intervention studies shows that prasterone supplementation in elderly men can induce a small but significant positive effect on body composition that is strictly dependent on prasterone conversion into its bioactive metabolites such as androgens or estrogens.
There is no evidence prasterone is of benefit in treating or preventing cancer. Although prasterone is postulated as an inhibitor towards glucose-6-phosphate dehydrogenase (G6PD) and suppresses leukemia cell proliferation in vitro, Prasterone may enhance G6PD mRNA expression, confounding its inhibitory effects.
A review in 2003 found the then-extant evidence sufficient to suggest that low serum levels of DHEA-S may be associated with coronary heart disease in men, but insufficient to determine whether prasterone supplementation would have any cardiovascular benefit.
A double-blind, placebo-controlled study in adult polydrug users in a detoxification program showed the efficacy of prasterone treatment combined with psychosocial enrichment and after-care. Prasterone administration positively affected decision-making, mood and well-being as early as one month into treatment, and had a long-lasting preventive effect on relapse to drug use. In a 16-month follow-up, relapse rates of prasterone-treated subjects were only 11.5%. No adverse symptoms were found. These findings demonstrate the long-term effect of prasterone on drug relapse.
Prasterone supplementation has not been found to be useful for memory function in normal middle aged or older adults. It has been studied as a treatment for Alzheimer's disease, but there is no evidence that it is effective.
Evidence is inconclusive in regards to the effect of prasterone on strength in the elderly.
- J. Elks (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 641–. ISBN 978-1-4757-2085-3.
- James Devillers (27 April 2009). Endocrine Disruption Modeling. CRC Press. pp. 339–. ISBN 978-1-4200-7636-3.
- Melanie Johns Cupp; Timothy S. Tracy (10 December 2002). Dietary Supplements: Toxicology and Clinical Pharmacology. Springer Science & Business Media. pp. 135–. ISBN 978-1-59259-303-3.
- B.J. Oddens; A. Vermeulen (15 November 1996). Androgens and the Aging Male. CRC Press. pp. 5–. ISBN 978-1-85070-763-9.
- Arlt, W (September 2004). "Dehydroepiandrosterone and ageing". Best practice & research. Clinical endocrinology & metabolism. 18 (3): 363–80. PMID 15261843. doi:10.1016/j.beem.2004.02.006.
- Alkatib, AA; Cosma, M; Elamin, MB; Erickson, D; Swiglo, BA; Erwin, PJ; Montori, VM (October 2009). "A systematic review and meta-analysis of randomized placebo-controlled trials of DHEA treatment effects on quality of life in women with adrenal insufficiency". The Journal of Clinical Endocrinology and Metabolism. 94 (10): 3676–81. PMID 19773400. doi:10.1210/jc.2009-0672.
- Paul M. Coates; M. Coates Paul; Marc Blackman; Marc R. Blackman, Gordon M. Cragg, Mark Levine, Jeffrey D. White, Joel Moss, Mark A. Levine (29 December 2004). Encyclopedia of Dietary Supplements (Print). CRC Press. pp. 169–. ISBN 978-0-8247-5504-1.
- Rogerio A. Lobo (5 June 2007). Treatment of the Postmenopausal Woman: Basic and Clinical Aspects. Academic Press. pp. 821–828. ISBN 978-0-08-055309-2.
- J. Horsky; J. Presl (6 December 2012). Ovarian Function and its Disorders: Diagnosis and Therapy. Springer Science & Business Media. pp. 146–. ISBN 978-94-009-8195-9.
- D. Platt (6 December 2012). Geriatrics 3: Gynecology · Orthopaedics · Anesthesiology · Surgery · Otorhinolaryngology · Ophthalmology · Dermatology. Springer Science & Business Media. pp. 6–. ISBN 978-3-642-68976-5.
- S. Campbell (6 December 2012). The Management of the Menopause & Post-Menopausal Years: The Proceedings of the International Symposium held in London 24–26 November 1975 Arranged by the Institute of Obstetrics and Gynaecology, The University of London. Springer Science & Business Media. pp. 395–. ISBN 978-94-011-6165-7.
- Carrie Bagatell; William J. Bremner (27 May 2003). Androgens in Health and Disease. Springer Science & Business Media. pp. 277–. ISBN 978-1-59259-388-0.
- Frigo P, Eppel W, Asseryanis E, Sator M, Golaszewski T, Gruber D, Lang C, Huber J (1995). "The effects of hormone substitution in depot form on the uterus in a group of 50 perimenopausal women--a vaginosonographic study". Maturitas. 21 (3): 221–5. PMID 7616871. doi:10.1016/0378-5122(94)00893-c.
- Schwartz AG, Pashko LL (2004). "Dehydroepiandrosterone, glucose-6-phosphate dehydrogenase, and longevity". Ageing Res. Rev. 3 (2): 171–87. PMID 15177053. doi:10.1016/j.arr.2003.05.001.
- Mortola JF, Yen SS (1990). "The effects of oral dehydroepiandrosterone on endocrine-metabolic parameters in postmenopausal women". J. Clin. Endocrinol. Metab. 71 (3): 696–704. PMID 2144295. doi:10.1210/jcem-71-3-696.
- John W. Blunt; Murray H. G. Munro (19 September 2007). Dictionary of Marine Natural Products with CD-ROM. CRC Press. pp. 1075–. ISBN 978-0-8493-8217-8.
- A. Kleemann; J. Engel; B. Kutscher; D. Reichert (14 May 2014). Pharmaceutical Substances, 5th Edition, 2009: Syntheses, Patents and Applications of the most relevant APIs. Thieme. pp. 2441–2442. ISBN 978-3-13-179525-0.
- Martin Negwer; Hans-Georg Scharnow (2001). Organic-chemical drugs and their synonyms: (an international survey). Wiley-VCH. p. 1831. ISBN 978-3-527-30247-5.
3β-Hydroxyandrost-5-en-17-one hydrogen sulfate = (3β)-3-(Sulfooxy)androst-5-en-17-one. R: Sodium salt (1099-87-2). S: Astenile, Dehydroepiandrosterone sulfate sodium, DHA-S, DHEAS, KYH 3102, Mylis, PB 005, Prasterone sodium sulfate, Teloin
- Jianqiu, Y. (1992). Clinical Application of Prasterone Sodium Sulfate. Chinese Journal of New Drugs, 5, 015.
- Sakaguchi M, Sakai T, Adachi Y, Kawashima T, Awata N (1992). "The biological fate of sodium prasterone sulfate after vaginal administration. I. Absorption and excretion in rats". J. Pharmacobio-dyn. 15 (2): 67–73. PMID 1403604.
- Sakai, T., Sakaguchi, M., Adachi, Y., Kawashima, T., & Awata, N. (1992). The Biological Fate of Sodium Prasterone Sulfate after Vaginal Administration II: Distribution after Single and Multiple Administration to Pregnant Rats. 薬物動態, 7(1), 87-101.
- Ades TB, ed. (2009). DHEA. American Cancer Society Complete Guide to Complementary and Alternative Cancer Therapies (2nd ed.). American Cancer Society. pp. 729–33. ISBN 9780944235713.
- Medscape (2010). "DHEA Oral". Drug Reference. WebMD LLC. Retrieved 18 February 2010.
- Chang DM, Lan JL, Lin HY, Luo SF (2002). "Dehydroepiandrosterone treatment of women with mild-to-moderate systemic lupus erythematosus: a multicenter randomized, double-blind, placebo-controlled trial". Arthritis Rheum. 46 (11): 2924–27. PMID 12428233. doi:10.1002/art.10615.
- Rabkin JG, McElhiney MC, Rabkin R, McGrath PJ, Ferrando SJ (2006). "Placebo-controlled trial of dehydroepiandrosterone (DHEA) for treatment of nonmajor depression in patients with HIV/AIDS". Am J Psychiatry. 163 (1): 59–66. PMID 16390890. doi:10.1176/appi.ajp.163.1.59.
- Brooke AM, Kalingag LA, Miraki-Moud F, Camacho-Hübner C, Maher KT, Walker DM, Hinson JP, Monson JP (2006). "Dehydroepiandrosterone improves psychological well-being in male and female hypopituitary patients on maintenance growth hormone replacement". J Clin Endocrinol Metab. 91 (10): 3773–79. PMID 16849414. doi:10.1210/jc.2006-0316.
- Villareal DT, Holloszy JO (2006). "DHEA enhances effects of weight training on muscle mass and strength in elderly women and men". Am J Physiol Endocrinol Metab. 291 (5): E1003–08. doi:10.1152/ajpendo.00100.2006.
- Medline Plus. "DHEA". Drugs and Supplements Information. National Library of Medicine. Retrieved 18 February 2010.
- "DHEA: Side effects and safety". WebMD. Retrieved 24 July 2012.
- I.K. Morton; Judith M. Hall (6 December 2012). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. pp. 92,96,230. ISBN 978-94-011-4439-1.
- Calfee, R.; Fadale, P. (March 2006). "Popular ergogenic drugs and supplements in young athletes". Pediatrics. 117 (3): e577–89. PMID 16510635. doi:10.1542/peds.2005-1429.
In 2004, a new Steroid Control Act that placed androstenedione under Schedule III of controlled substances effective January 2005 was signed. DHEA was not included in this act and remains an over-the-counter nutritional supplement.
- "Drug Scheduling Actions – 2005". Drug Enforcement Administration.
- Health Canada, DHEA listing in the Ingredient Database
- Therapeutic Goods Administration, Personal Importation Scheme
- World Anti-Doping Agency
- Memphis Grizzlies' O. J. Mayo gets 10-game drug suspension, ESPN, January 27, 2011.
- Memphis Grizzlies' O. J. Mayo suspended 10 games for violating NBA anti-drug program
- "US 400m star LaShawn Merritt fails drug test". BBC Sport. 22 April 2010.
- Russian Olympic Medal-Winning Swimmer Efimova Fails Doping Test – Report
- Fabio Maldonado plans to use DHEA for Fedor match, admits use in UFC
- Corona, G; Rastrelli, G; Giagulli, VA; Sila, A; Sforza, A; Forti, G; Mannucci, E; Maggi, M (2013). "Dehydroepiandrosterone supplementation in elderly men: a meta-analysis study of placebo-controlled trials". J. Clin. Endocrinol. Metab. 98: 3615–26. PMID 23824417. doi:10.1210/jc.2013-1358.
- Di Monaco M, Pizzini A, Gatto V, Leonardi L, Gallo M, Brignardello E, Boccuzzi G (1997). "Role of glucose-6-phosphate dehydrogenase inhibition in the antiproliferative effects of dehydroepiandrosterone on human breast cancer cells". Br J Cancer. 75: 589–92. PMC . PMID 9052415. doi:10.1038/bjc.1997.102.
- Xu SN, Wang TS, Li X, Wang YP (Sep 2016). "SIRT2 activates G6PD to enhance NADPH production and promote leukaemia cell proliferation". Sci Rep. 6: 32734. PMC . PMID 27586085. doi:10.1038/srep32734.
- Hecker PA, Leopold JA, Gupte SA, Recchia FA, Stanley WC (Feb 2013). "Impact of glucose-6-phosphate dehydrogenase deficiency on the pathophysiology of cardiovascular disease". Am J Physiol Heart Circ Physiol. 304: H491–500. PMC . PMID 23241320. doi:10.1152/ajpheart.00721.2012.
- Thijs L, Fagard R, Forette F, Nawrot T, Staessen JA (October 2003). "Are low dehydroepiandrosterone sulphate levels predictive for cardiovascular diseases? A review of prospective and retrospective studies". Acta Cardiol. 58 (5): 403–10. PMID 14609305. doi:10.2143/AC.58.5.2005304.
- Ohana, D; Maayan, R; Delayahu, Y; Roska, P; Ponizovsky, AM; Weizman, A; Yadid, G; Yechiam, E (March 2015). "Effect of dehydroepiandrosterone add-on therapy on mood, decision making and subsequent relapse of polydrug=Addiction Biology :". 21 (4): 885–94. PMID 25818161.
- Crosbie, D; Black, C; McIntyre, L; Royle, PL; Thomas, S (Oct 17, 2007). Crosbie, David, ed. "Dehydroepiandrosterone for systemic lupus erythematosus". Cochrane database of systematic reviews (Online) (4): CD005114. PMID 17943841. doi:10.1002/14651858.CD005114.pub2.
- Grimley Evans, J; Malouf, R; Huppert, F; van Niekerk, JK (Oct 18, 2006). Malouf, Reem, ed. "Dehydroepiandrosterone (DHEA) supplementation for cognitive function in healthy elderly people". Cochrane database of systematic reviews (Online) (4): CD006221. PMID 17054283. doi:10.1002/14651858.CD006221.
- Fuller, SJ; Tan, RS; Martins, RN (September 2007). "Androgens in the etiology of Alzheimer's disease in aging men and possible therapeutic interventions". Journal of Alzheimer's disease : JAD. 12 (2): 129–42. PMID 17917157.
- Pluchino, N; Drakopoulos, P; Bianchi-Demicheli, F; Wenger, JM; Petignat, P; Genazzani, AR (January 2015). "Neurobiology of DHEA and effects on sexuality, mood and cognition.". The Journal of steroid biochemistry and molecular biology. 145: 273–80. PMID 24892797. doi:10.1016/j.jsbmb.2014.04.012.
- Maric, NP; Adzic, M (September 2013). "Pharmacological modulation of HPA axis in depression - new avenues for potential therapeutic benefits." (PDF). Psychiatria Danubina. 25 (3): 299–305. PMID 24048401.
- Baker, WL; Karan, S; Kenny, AM (June 2011). "Effect of dehydroepiandrosterone on muscle strength and physical function in older adults: a systematic review". Journal of the American Geriatrics Society. 59 (6): 997–1002. PMID 21649617. doi:10.1111/j.1532-5415.2011.03410.x.
- Wallace, M. B.; Lim, J.; Cutler, A.; Bucci, L. (1999). "Effects of dehydroepiandrosterone vs androstenedione supplementation in men". Medicine and Science in Sports and Exercise. 31 (12): 1788–92. PMID 10613429. doi:10.1097/00005768-199912000-00014.
- Information on DHEA from the Mayo Clinic
- DHEA in elderly women and DHEA or testosterone in elderly men, published in the New England Journal of Medicine in 2006. "Neither DHEA nor low-dose testosterone replacement in elderly people has physiologically relevant beneficial effects on body composition, physical performance, insulin sensitivity, or quality of life."
- DHEA, from the Skeptic's Dictionary
- ChemSub Online: Dehydroepiandrosterone - DHEA